AU2003287267A1 - Lutzomyia longipalpis polypeptides and methods of use - Google Patents

Lutzomyia longipalpis polypeptides and methods of use

Info

Publication number
AU2003287267A1
AU2003287267A1 AU2003287267A AU2003287267A AU2003287267A1 AU 2003287267 A1 AU2003287267 A1 AU 2003287267A1 AU 2003287267 A AU2003287267 A AU 2003287267A AU 2003287267 A AU2003287267 A AU 2003287267A AU 2003287267 A1 AU2003287267 A1 AU 2003287267A1
Authority
AU
Australia
Prior art keywords
disclosed
methods
polypeptides
lutzomyia longipalpis
longipalpis polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287267A
Other languages
English (en)
Other versions
AU2003287267A8 (en
Inventor
Aldina Barral
Claudia Brodskyn
Regis Gomes
Manoel Netto
Jose M.C. Ribeiro
Jesus G. Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRO DE PESQUISAS GONCALO MONIZ
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2003287267A1 publication Critical patent/AU2003287267A1/en
Publication of AU2003287267A8 publication Critical patent/AU2003287267A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003287267A 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use Abandoned AU2003287267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42230302P 2002-10-29 2002-10-29
US60/422,303 2002-10-29
PCT/US2003/034453 WO2004039958A2 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use

Publications (2)

Publication Number Publication Date
AU2003287267A1 true AU2003287267A1 (en) 2004-05-25
AU2003287267A8 AU2003287267A8 (en) 2004-05-25

Family

ID=32230337

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287267A Abandoned AU2003287267A1 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use

Country Status (10)

Country Link
US (6) US7485306B2 (enExample)
EP (2) EP1572968B1 (enExample)
JP (2) JP2006516187A (enExample)
AT (1) ATE429487T1 (enExample)
AU (1) AU2003287267A1 (enExample)
BR (1) BR0315872A (enExample)
DE (1) DE60327366D1 (enExample)
ES (1) ES2447843T3 (enExample)
MX (1) MXPA05004714A (enExample)
WO (1) WO2004039958A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP1572968B1 (en) * 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
EP2283035B1 (en) * 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
WO2010021940A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insect proteins as adjuvants to accelerate the immune response
JP5590986B2 (ja) 2010-06-23 2014-09-17 株式会社シマノ 釣り用リールのワンウェイクラッチ
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0260148A3 (en) 1986-09-12 1989-06-07 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5397772A (en) * 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
DE69225710T3 (de) 1991-07-25 2004-10-14 Idec Pharmaceuticals Corp., San Diego Anregung von antworten zytotoxischer t-lymphozyten
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995006729A1 (en) 1993-09-03 1995-03-09 Mcgill University Differentially expressed leishmania genes and proteins
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
WO1996002668A1 (en) 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
AU2002347464A1 (en) 2001-06-19 2003-01-02 The Gouvernment Of The United States Of America, As Represented By The Secretary Department Of Healt Anti-arthropod vector vaccines methods of selecting and uses thereof
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP1572968B1 (en) * 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use

Also Published As

Publication number Publication date
US9382302B2 (en) 2016-07-05
US10314900B2 (en) 2019-06-11
WO2004039958A3 (en) 2005-12-08
EP1572968B1 (en) 2009-04-22
EP2085467A2 (en) 2009-08-05
US20140093531A1 (en) 2014-04-03
ES2447843T3 (es) 2014-03-13
DE60327366D1 (de) 2009-06-04
EP1572968A2 (en) 2005-09-14
JP2010142226A (ja) 2010-07-01
WO2004039958A2 (en) 2004-05-13
EP2085467B1 (en) 2013-12-11
US20150315254A1 (en) 2015-11-05
US9120867B2 (en) 2015-09-01
MXPA05004714A (es) 2006-03-17
JP2006516187A (ja) 2006-06-29
ATE429487T1 (de) 2009-05-15
US20090117139A1 (en) 2009-05-07
BR0315872A (pt) 2006-07-18
AU2003287267A8 (en) 2004-05-25
EP2085467A3 (en) 2009-10-14
EP1572968A4 (en) 2006-07-19
US9884100B2 (en) 2018-02-06
US8628780B2 (en) 2014-01-14
US7485306B2 (en) 2009-02-03
US20160279211A1 (en) 2016-09-29
US20060051364A1 (en) 2006-03-09
US20180147269A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
GB0227346D0 (en) 741
GB2331825B (en) Personal identification authenticating with fingerprint identification
AU2003287267A1 (en) Lutzomyia longipalpis polypeptides and methods of use
DE60043158D1 (de) Heteroklitische analoga von klasse-i epitopen
AU2002360331A8 (en) Egviii endoglucanase and nucleic acids encoding the same
AU9435098A (en) Tuberculosis vaccine
CA2168429A1 (en) Expression of fusion polypeptides transported out of cytoplasm without leader sequences
WO2000071754A3 (en) Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
ATE302789T1 (de) Zellkernmatrixproteine
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
AU2003223934A8 (en) Recombinant bet. v. 1. allergen mutants, methods and process thereof
DE59810198D1 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
DK1098972T3 (da) Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
WO2002081517A3 (en) Novel polypeptides and nucleic acids encoded thereby
WO2004027041A3 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
ITAR930018A0 (it) Bussola di sicurezza con identificatore biometrico
AU9730798A (en) Epoxide hydrolase
AU2043597A (en) Human taki dna encoding the same
CA2197651A1 (en) Or-1 on orphan receptor belonging to the nuclear receptor family
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
DE69711285D1 (de) Krimpmutter mit eingebettetem Kopf
AU7922998A (en) Bow of spectacles maintained by the hair
AU6261300A (en) A method of testing a person's personal characteristics as well as a system for feedback of the result of such a test
WO1999029720A3 (en) Mammalian alpha helical protein-1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 24, PAGE(S) 6812 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2003287267, UNDER INID (71) CORRECT THE NAME TO READ CENTRO DE PESQUISAS GONCALO MONIZ; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES